Ex-Al­ler­gan prez In­gram forges $1B deal to sell Alzheimer’s biotech to Brent Saun­ders and the new crew at Al­ler­gan

Brent Saun­ders, Al­ler­gan

Just a year af­ter ex-Al­ler­gan pres­i­dent Doug In­gram took the helm of a low-pro­file biotech named Chase Phar­ma­ceu­ti­cals and helped steer an ex­per­i­men­tal ther­a­py for Alzheimer’s through a suc­cess­ful, though small, Phase II study, he’s arranged a sale of the com­pa­ny to Brent Saun­ders and the new team run­ning Al­ler­gan.

Al­ler­gan CEO Saun­ders agreed to hand over $125 mil­lion in a cash up­front to ac­quire Irvine, CA-based Chase, and a spokesper­son for the com­pa­ny says mile­stones bring the to­tal val­ue of the deal up to a po­ten­tial $1 bil­lion.

Al­ler­gan gets a small pipeline, but the deal is be­ing dri­ven by its de­sire for CPC-201. While a num­ber of new drugs in the Alzheimer’s sec­tor are try­ing to bend the curve on dis­ease pro­gres­sion, CPC-201 has a much more mod­est goal in mind. The drug is de­signed to al­low pa­tients to height­en their dose of donepezil, which is used to help con­trol symp­toms of the mem­o­ry-wast­ing ail­ment.

Doug In­gram, Chase Phar­ma­ceu­ti­cals

The deal al­so spot­lights Al­ler­gan’s hunger for new drugs it can push in­to late-stage test­ing. It’s ac­quired a grow­ing line­up of biotechs in the months since its merg­er with Pfiz­er fell through. And Saun­ders has made it clear to me that this kind of steady flow of ac­qui­si­tions is a part of Al­ler­gan’s busi­ness mod­el now.

The deal marks a sig­nif­i­cant suc­cess for Chase’s in­vestors, which have backed the biotech with $24 mil­lion. The cash up­front is worth more than 5X, and there’s much, much more on the ta­ble if the Phase III works.

In­gram took over as CEO of Chase last fall, just months af­ter Saun­ders stepped in to merge the com­pa­ny in­to Ac­tavis, keep­ing the Al­ler­gan name in that buy­out. In­gram stepped out of his role at Al­ler­gan at the time, though he agreed to help as an ad­vis­er.

In Phase II, 29 out of 33 pa­tients were able to tol­er­ate a 40 mg max­i­mum dose of the drug with­out trig­ger­ing se­ri­ous side ef­fects. If that plays out in a much larg­er late-stage tri­al, Al­ler­gan be­lieves it will have a much-need­ed ther­a­py that can be added to the very lim­it­ed phar­ma­copeia that ex­ists cur­rent­ly in Alzheimer’s.

Bern­stein an­a­lysts gave the deal a quick thumbs up. They wrote:

Our view:  as­sum­ing the da­ta af­firms the news, this is cer­tain­ly an in­trigu­ing prod­uct and well worth the $125M spent on the ac­qui­si­tion.  A decade ago, this could have been a mul­ti-bil­lion block­buster drug.  Now, it seems more de­pen­dent on how good the amy­loid be­ta based drugs will be.  Still, we ex­pect that for pa­tients who are can­di­dates for Ari­cept, this could be an im­prove­ment.   Fur­ther, giv­en AGN ex­ist­ing com­mer­cial in­fra­struc­ture, the re­turn on in­vest­ment could be high.

“We be­lieve our lead can­di­date, CPC-201, will of­fer a sig­nif­i­cant im­prove­ment over ex­ist­ing ther­a­py in the symp­to­matic treat­ment of Alzheimer’s dis­ease, and will ben­e­fit all those suf­fer­ing from this dis­ease,” said Thomas Chase, co-founder and Chief Sci­en­tif­ic Of­fi­cer of Chase Phar­ma­ceu­ti­cals.

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

Acadia’s late-stage program to widen the commercial prospects for Nuplazid has hit a wall. The biotech reported that their Phase III ENHANCE trial flat failed. And while they $ACAD did their best to cherry pick positive data wherever they can be found, this is a clear setback for the biotech.

With close to 400 patients enrolled, researchers said the drug flunked the primary endpoint as an adjunctive therapy for patients with an inadequate response to antipsychotic therapy. The p-value was an ugly 0.0940 on the Positive and Negative Syndrome Scale, which the company called out as a positive trend.

Their shares slid 12% on the news, good for a $426 million hit on a $3.7 billion market cap at close.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.

In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

Intec Pharma’s $NTEC lead drug slammed into a brick wall Monday morning. The small-cap Israeli biotech reported that its lead program — coming off a platform designed to produce a safer, more effective oral drug for Parkinson’s — failed the Phase III at the primary endpoint.

Researchers at Intec, which has already seen its share price collapse over the past few months, says that its Accordion Pill-Carbidopa/Levodopa failed to prove superior to Sinemet in reducing daily ‘off’ time. 

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Whoever is taking Otezla off Bristol-Myers Squibb’s hands will have one more revenue stream to boast.

The drug — a rising star in Celgene’s pipeline that generated global sales of $1.6 billion last year — is now OK’d to treat oral ulcers associated with Behçet’s disease, a common symptom for a rare inflammatory disorder. This marks the third FDA approval for the PDE4 inhibitor since 2014, when it was greenlighted for plaque psoriasis and psoriatic arthritis.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric (Biohaven)

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

Biohaven is at risk of making a habit of disappointing its investors.

Late Friday the biotech $BHVN reported that the FDA had rejected its application for riluzole, an old drug that they had made over into a sublingual formulation that dissolves under the tongue. According to Biohaven, the FDA had a problem with the active ingredient used in a bioequivalence study back in 2017, which they got from the Canadian drugmaker Apotex.

Apotex, though, has been a disaster ground. The manufacturer voluntarily yanked the ANDAs on 31 drugs — in late 2017 — after the FDA came across serious manufacturing deficiencies at their plants in India. A few days ago, the FDA made it official.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.